Home Cart 0 Sign in  

[ CAS No. 117976-90-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 117976-90-6
Chemical Structure| 117976-90-6
Structure of 117976-90-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 117976-90-6 ]

Related Doc. of [ 117976-90-6 ]

Alternatived Products of [ 117976-90-6 ]

Product Details of [ 117976-90-6 ]

CAS No. :117976-90-6 MDL No. :MFCD02092688
Formula : C18H20N3NaO3S Boiling Point : -
Linear Structure Formula :- InChI Key :KRCQSTCYZUOBHN-UHFFFAOYSA-N
M.W : 381.42 Pubchem ID :14720269
Synonyms :
LY307640 sodium;Rabeprazole (sodium salt);dexrabeprazole;3810, E;Rebeprazole sodium;Aciphex;Pariet;LY307640;E 3810;Habeprazole Sodium;Dexrabeprazole Sodium;Aciphex Sodium;Rabeprazole sodium
Chemical Name :Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Calculated chemistry of [ 117976-90-6 ]

Physicochemical Properties

Num. heavy atoms : 26
Num. arom. heavy atoms : 15
Fraction Csp3 : 0.33
Num. rotatable bonds : 8
Num. H-bond acceptors : 6.0
Num. H-bond donors : 0.0
Molar Refractivity : 96.72
TPSA : 93.41 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.14 cm/s

Lipophilicity

Log Po/w (iLOGP) : -11.51
Log Po/w (XLOGP3) : 2.1
Log Po/w (WLOGP) : 3.33
Log Po/w (MLOGP) : 0.88
Log Po/w (SILICOS-IT) : 3.29
Consensus Log Po/w : -0.38

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.43
Solubility : 0.143 mg/ml ; 0.000374 mol/l
Class : Soluble
Log S (Ali) : -3.69
Solubility : 0.0775 mg/ml ; 0.000203 mol/l
Class : Soluble
Log S (SILICOS-IT) : -6.9
Solubility : 0.0000478 mg/ml ; 0.000000125 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.7

Safety of [ 117976-90-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 117976-90-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 117976-90-6 ]
  • Downstream synthetic route of [ 117976-90-6 ]

[ 117976-90-6 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 117976-90-6 ]
  • [ 60-24-2 ]
  • [ 7673-83-8 ]
  • [ 117977-21-6 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1996, vol. 44, # 3, p. 552 - 558
  • 2
  • [ 117976-89-3 ]
  • [ 117976-90-6 ]
YieldReaction ConditionsOperation in experiment
100% With sodium hydroxide In ethanol Example 2 Ethanol (30 ml) was added to sodium hydroxide (2.25 g (55.1 mmol)), and dissolution was carried out. 2-[{4-(3-Methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole (20.0 g (55.6 mmol)) was then put into the ethanol solution, and after dissolution had been confirmed, diisopropyl ether (2000 ml) was added slowly, whereby 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole sodium salt (22.8 g) was obtained through precipitation (yield 100percent).; Example 3 Ethanol (22.5 ml) was added to sodium hydroxide (1.65 g (41.3 mmol)), and dissolution was carried out. 2-[{4-(3-Methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole (15.0 g (41.7 mmol)) was then put into the ethanol solution, and after dissolution had been confirmed, tert-butyl methyl ether (160 ml) was added slowly, whereby 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole sodium salt (15.9 g) was obtained through precipitation (yield 100percent).
100% With sodium hydroxide In water Reference Example 17; Sodium hydroxide (0.557 g) was dissolved in ion exchange water (5 ml). 2-[{4-(3-Methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole (4.96 g) was then put into the solution, and after dissolution had been confirmed, freeze drying was carried out for 22 hours using a bottle-type freeze dryer, thus obtaining 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]1H-benzimidazole sodium salt quantitatively.; Reference Example 18; Sodium hydroxide (0.560 g) was dissolved in ion exchange water (10 ml). 2-[{4-(3-Methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole (4.98 g) was then put into solution, and after dissolution had been confirmed, freeze drying was carried out for 22 hours using a bottle-type freeze dryer, thus obtaining 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole sodium salt quantitatively.; Reference Example 19; Sodium hydroxide (0.507 g) was dissolved in ion exchange water (15 ml). 2-[{4-(3-Methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole (4.50 g) was then put into the solution, and after dissolution had been confirmed, freeze drying was carried out for 22 hours using a bottle-type freeze dryer, thus obtaining 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole sodium salt quantitatively.; Reference Example 20; Sodium hydroxide (0.506 g) was dissolved in ion exchange water (25 ml). 2-[{4-(3-Methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole (4.50 g) was then put into the solution, and after dissolution had been confirmed, freeze drying was carried out for 22 hours using a bottle-type freeze dryer, thus obtaining 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole sodium salt quantitatively.; Reference Example 21; Sodium hydroxide (0.556 g) was dissolved in ion exchange water (10 ml). 2-[{4-(3-Methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole (5.00 g) was then put into the solution, and after dissolution had been confirmed, the solution was put into a Tray-type freeze dryer and freeze drying was carried out, thus obtaining 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole sodium salt quantitatively. Here, the Tray temperature was raised to 25° C.
98% With sodium carbonate; 2-fluoro-3-chloro-5-(trifluoromethyl)pyridine In ethanol at 35 - 40℃; for 2 h; Example 2:
500ml 2- fluoro-3-chloro-5-trifluoromethylpyridine in ethanol (2-fluoro-3-chloro-5-trifluoromethylpyridine:ethanol 1:1) was added with 30g rabeprazole, regulation temperature 36°C; to the reaction mixture was added 2g anhydrous sodium carbonate, dried over 1g anhydrous sodium sulfate, the reaction solution was measured at pH 9.0, maintaining the temperature at 35°C-40°C, the reaction was stirred for 2 hours. 1g of activated carbon was added, 0.5 hours decolorization, suction filtered, 400ml of n-hexane was added, the reaction was stirred for 2 hours at 36°C, suction filtered, the filter cake was washed with an appropriate amount of n-hexane, and dried, giving 32.3g white powder, yield 98.00percent, purity 99.9 percent.
97% With sodium hydroxide In water at 4 - 5℃; Sodium hydroxide (5.62 g) was dissolved in DM water (200 ml) and cooled to [4-5°C.] Rabeprazole (50 g) was added and mixture stirred to obtain a clear solution. The solution was treated with 2 g of carbon DC-enoanticromos for 30 min at [5-10°C.] Carbon was removed by filtration and residue washed with DM water (2x25 ml). The contents were [LYOPHILIZED] using standard method. Rabeprazole sodium was obtained as a white powder.
94.9% With sodium hydroxide In methanol at 25 - 35℃; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole (obtained as per reference example 1) (50.0 grams, 0.139 moles) was dissolved in a mixture of sodium hydroxide (7.5 grams, 0.187 moles) and methanol (100.0 ml), and the solution was stirred at ambient temperature 25-35 °C. The reaction solution is filtered through hi-flow and washed with methanol (50.0 ml). Then, the solvent of the filtrate was distilled off under reduced pressure. The reaction mass was cooled to ambient temperature, and petroleum ether (400.0 ml) was then added to the residual mass, which was then stirred at 25-30 °C for about 1-2 hours. The precipitated solid was filtered and washed with petroleum ether (100.0 ml) and dried at 50-60°C for 12 hours to afford the desired amorphous form of rabeprazole sodium (Weight: 50.4 grams, 94.9percent).
94.9% With sodium hydroxide In methanol at 25 - 35℃; for 1 h; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole (obtained by reference example 1) (50.0 grams, 0.139 moles) was dissolved in a mixture of sodium hydroxide (7.5 grams, 0.187 moles) and methanol (100.0 ml), and the resulted solution was stirred at ambient temperature 25-35°C for about one hour. The reaction solution was filtered through hi-flow and washed with methanol (50.0 ml). Then the solvent of the filtrate was distilled off under reduced pressure. The reaction mass is cooled to ambient temperature, to which toluene (200.0 ml) was added. The residual mass was then refluxed for about 2-6 hours. After cooling the reaction solution, the precipitated solid was filtered, washed with toluene (100.0 ml) and dried at 90-100°C for 12 hours to afford the desired form Z ofrabeprazole sodium (Weight: 50.4 grams, 94.9percent).
94.9% With sodium hydroxide In methanol at 25 - 35℃; 2-[[[4-(3-methoxypropoxy)-3-melhyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole (obtained by reference example 1) (50.0 grams, 0.139 moles) was dissolved in a mixture of sodium hydroxide (7.5 grams, 0.187 moles) and methanol (100.0 ml) and stirred at ambient temperature 25-35°C. The reaction solution was filtered through hi-flow and washed with methanol (50-0 ml). Then the solvent of the filtrate was distilled off under reduced pressure. The reaction mass was cooled to ambient temperature. Dichloromethane (100.0 ml) was added to the reaction mixture, which was then distilled to remove traces of methanol. Dichloromethane (50.0 ml) and petroleum ether (100.0 ml) was then added to the residual mass, which was then stirred at 25-30 °C for about 6-8 hours. Additional petroleum ether (150 ml) was added to the reaction mixture, which was stirred at 25-30 °C for 1-2 hours. The precipitated solid was filtered and washed with petroleum ether (100.0 ml) and dried at 50-60°C for 12 hours to afford the desired form X of rabeprazole sodium (Weight: 50.4 grams, 94.9percent).
94.9% With sodium hydroxide In methanol at 25 - 35℃; for 1 h; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole (obtained by reference example 1) (50.0 grams, 0.139 moles) was dissolved in a mixture of sodium hydroxide (7.5 grams, 0.187 moles) and methanol (100.0 ml), and the resulted solution was stirred at ambient temperature 25-35° C. for about one hour. The reaction solution was filtered through hi-flow and washed with methanol (50.0 ml). Then the solvent of the filtrate was distilled off under reduced pressure. The reaction mass is cooled to ambient temperature, to which toluene (200.0 ml) was added. The residual mass was then refluxed for about 2-6 hours. After cooling the reaction solution, the precipitated solid was filtered, washed with toluene (100.0 ml) and dried at 90-100° C. for 12 hours to afford the desired form Z of rabeprazole sodium (Weight: 50.4 grams, 94.9percent).
94.9%
Stage #1: With sodium hydroxide In methanol at 20℃;
Stage #2: at 25 - 30℃; for 6 - 8 h;
Example 1; Preparation Of Crystalline Form-X Of Rabeprazole Sodium 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-lH- benzimidazole (obtained as per reference example) (50.0 grams, 0.139 moles) is dissolved in a mixture of sodium hydroxide (7.5 grams, 0.187 moles) and methanol (100.0 ml) and stirred at ambient temperature. The reaction solution is filtered through hi-flow and washed with methanol (50.0 ml). Methanol from the filtrate is distilled off under high vacuum. The reaction mass is cooled to ambient temperature followed by addition of dichloromethane (100.0 ml) accompanied by distillation to remove traces of methanol. Dichloromethane (50.0 ml) and petroleum ether (100.0 ml) is then added to the residual mass, which is then stirred at 25-30°C for about 6-8 hours. The solid that is obtained further diluted with petroleum ether (150 ml) and stirred at 25-30°C for about 6-8 hours. The precipitated solid is filtered and washed with petroleum ether (100.0 ml) and dried at 50-60°C for 12 hours to afford the desired Form X of Rabeprazole sodium (Weight: 50.4 grams, 94.9percent). The X-ray Diffraction Pattern, Differential Scanning Calorimetry thermogram of Form X of Rabeprazole sodium obtained in above example is in accordance with Figure 1 and 2 respectively.
94% at 20 - 30℃; Inert atmosphere 1.73 g (0.075 mol) of sodium metal was dissolved in 120 ml of methanol at room temperature under nitrogen atmosphere. 27 g (0.075 mol) of 2-[[[4-(3-methoxy propoxy)- 3 -methyl-2-pyridinyl)] methyl] sulfinyl]-lH-benzimidazole was added to the solution at room temperature. The obtained mixture was stirred for 15 minutes to get clear solution. The clear reaction mass was stirred at 300C for one hour. 2.7 g of activated charcoal was added stirred for one hour (30+/-2 0C). Filtered the reaction mixture, the clear filtrate was concentrated under reduced pressure to obtain 29 g of crude title compound. The above crude solid was crystallized from a mixture of 87 ml methylene dichloride and 290 ml of t-butyl methyl ether in a nitrogen atmosphere to obtain 27 g (94percent) of title compound
93% With sodium hydroxide In methanol at 20℃; for 1 h; 1L of three-necked flask, was added 4g (0.1mol) in 100ml of methanol solution of sodium hydroxide, followed by addition of 36g of rabeprazole (0.1 mol), the reaction was stirred for 1h at room temperature to give a clear solution.Filtered and the filtrate rotary crude done.Room temperature using 150ml The crude product was dissolved in dichloromethane, and then 400ml of n-heptane was slowly added dropwise, the solution gradually became cloudy, and then stirred at room temperature after the addition was complete 1h.Filtered off with suction, the filter cake was rinsed with n-heptane alkoxy filter cake in a vacuum oven, 40-45 blast drying 12h, weighed to obtain rabeprazole sodium finished 35.62g (0.093mol), 93percent yield.
91.1% With sodium hydroxide In methanol at 25 - 35℃; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole (obtained as per reference example 1) (750.0 grams, 2.089 moles) was dissolved in a mixture of sodium hydroxide (112.5 grams, 2.8125 moles) and methanol (1500.0 ml), and the resulting solution was stirred at ambient temperature 25-35°C. The reaction solution was filtered through hi-flow and washed with methanol (750.0 ml). The solvent of the filtrate was distilled off completely under reduced pressure. The reaction mass was cooled to ambient temperature, and dichloromethane (1500.0 ml) was added to the reaction mass. The solvent was distilled again to remove traces of methanol. The reaction mass was cooled to ambient temperature, and n-butanol (375.0 ml) and tertiary butyl methyl ether (6.0 L) was added to the residual mass which is stirred at 25-30°C for 6-8 hours. The reaction mixture was further cooled to 5-15 °C and then stirred for another 3-5 hours. The solid then precipitated was filtered and washed with tertiary butyl methyl ether (1500.0 ml) and dried at 50-60°C for 7 hours to afford the desired crystalline Form Y of rabeprazole sodium (Weight: 725.0 grams, 91.1percent).
91.1% With sodium hydroxide In methanol at 25 - 35℃; for 1 h; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole (obtained as per reference example 1) (50.0 grams, 0.139 moles) was dissolved in a mixture of sodium hydroxide (7.5 grams, 0.187 moles) and methanol (100.0 ml), and the solution was stirred at ambient temperature 25-35° C. The reaction solution is filtered through hi-flow and washed with methanol (50.0 ml). Then, the solvent of the filtrate was distilled off under reduced pressure. The reaction mass was cooled to ambient temperature, and petroleum ether (400.0 ml) was then added to the residual mass, which was then stirred at 25-30° C. for about 1-2 hours. The precipitated solid was filtered and washed with petroleum ether (100.0 ml) and dried at 50-60° C. for 12 hours to afford the desired amorphous form of rabeprazole sodium (Weight: 50.4 grams, 94.9percent). REFERENCE EXAMPLE 3 [0052] Preparation of Crystalline form X of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole sodium (Rabeprazole Sodium) [0053] 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole (obtained by reference example 1) (50.0 grams, 0.139 moles) was dissolved in a mixture of sodium hydroxide (7.5 grams, 0.187 moles) and methanol (100.0 ml) and stirred at ambient temperature 25-35° C. The reaction solution was filtered through hi-flow and washed with methanol (50.0 ml). Then the solvent of the filtrate was distilled off under reduced pressure. The reaction mass was cooled to ambient temperature. Dichloromethane (100.0 ml) was added to the reaction mixture, which was then distilled to remove traces of methanol. Dichloromethane (50.0 ml) and petroleum ether (100.0 ml) was then added to the residual mass, which was then stirred at 25-30° C. for about 6-8 hours. Additional petroleum ether (150 ml) was added to the reaction mixture, which was stirred at 25-30° C. for 1-2 hours. The precipitated solid was filtered and washed with petroleum ether (100.0 ml) and dried at 50-60° C. for 12 hours to afford the desired form X of rabeprazole sodium (Weight: 50.4 grams, 94.9percent). REFERENCE EXAMPLE 4 [0054] Preparation of Crystalline form-Y of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole sodium (Rabeprazole Sodium) [0055] 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole (obtained as per reference example 1) (750.0 grams, 2.089 moles) was dissolved in a mixture of sodium hydroxide (112.5 grams, 2.8125 moles) and methanol (1500.0 ml), and the resulting solution was stirred at ambient temperature 25-35° C. The reaction solution was filtered through hi-flow and washed with methanol (750.0 ml). The solvent of the filtrate was distilled off completely under reduced pressure. The reaction mass was cooled to ambient temperature, and dichloromethane (1500.0 ml) was added to the reaction mass. The solvent was distilled again to remove traces of methanol. The reaction mass was cooled to ambient temperature, and n-butanol (375.0 ml) and tertiary butyl methyl ether (6.0 L) was added to the residual mass which is stirred at 25-30° C. for 6-8 hours. The reaction mixture was further cooled to 5-15° C. and then stirred for another 3-5 hours. The solid then precipitated was filtered and washed with tertiary butyl methyl ether (1500.0 ml) and dried at 50-60° C. for 7 hours to afford the desired crystalline Form Y of rabeprazole sodium (Weight: 725.0 grams, 91.1percent).
91.1%
Stage #1: With sodium hydroxide In methanol at 20℃;
Stage #2: at 5 - 30℃; for 9 - 13 h;
Example 2; Preparation Of Crystalline Form-Y Of Rabeprazole Sodium 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H- benzimidazole (obtained as per reference example) (750.0 grams, 2.089 moles) is dissolved in a mixture of sodium hydroxide (112.5 grams, 2. 8125 moles) and methanol (1500.0 ml) and stirred at ambient temperature. The reaction solution is filtered through hi-flow and washed with methanol (750.0 ml). Methanol from the filtrate is distilled off under high vacuum. The reaction mass is cooled to ambient temperature followed by addition of dichloromethane (1500.0 ml) accompanied by distillation to remove traces of methanol. The reaction mass is cooled to ambient temperature and n-butanol (375.0 ml) and tertiary butyl methyl ether (6.0 lit) is added to the residual mass which is stirred at 25- 30°C for 6-8 hours. The reaction mixture is further cooled to 5-15°C and then stirred for another 3-5 hours. The solid is thus obtained is filtered and washed with tertiary butyl methyl ether (1500.0 ml) and dried at 50-60°C for 7 hours to afford the desired crystalline Form Y of Rabeprazole sodium (Weight: 725.0 grams 91. 1percent). The X-ray Diffraction Pattern, Differential Scanning Calorimetry thermogram of Form Y of Rabeprazole sodium obtained in the example is in accordance with Figure 3 and 4 respectively.
90.3% With sodium hydroxide In methanol Example 1 2-[{4-(3-Methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole (4.97 g (13.8 mmol)) was dissolved in methanol (5 ml). Sodium hydroxide (0.559 g (13.7 mmol)) was then put into the methanol solution, and after dissolution had been confirmed, dipropyl ether (500 ml) was added slowly, whereby 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole sodium salt (4.77 g) was obtained through precipitation (yield 90.3percent).
90%
Stage #1: Heating / reflux
Stage #2: at 30℃; for 1 h;
Example- 1 Preparation of amorphous Rabeprazole sodium3.03 gm of freshly cut clean sodium metal was dissolved in 500 ml of tert. butyl alcohol under nitrogen atmosphere by refluxing to give a clear solution which was cooled to about 25-300C. Rabeprazole (50 gm) was added to it at about 300C and stirred for about one hour to give an orange brown solution. The <n="7"/>reaction mass was treated with about 2.5 gm of activated charcoal and stirred at 27-300C for about one hour. The reaction mass was filtered using hyio bed and λvashed with about 50 ml of tert. butyl alcohol. The filtered solution was distilled under vacuum at 40-500C to remove lert.butyl alcohol, high vacuum was applied for about 30 min to remove traces of lert. butyl alcohol. 750 ml of diisopropyl ether were added to the viscous mass, and stirred under nitrogen at 27-300C for about one hour. Off-white, amorphous powder of rabeprazole-Na salt was obtained, which was filtered under nitrogen and washed with 50 ml of diisopropyl ether. The product was dried under vacuum at 65-700C for about 48 hours to give amorphous rabeprazole sodium. Wt. of rabeprazole sodium = 47 gms percent yield = 90 percent purity > 99 percent percent water by ICF. < 4 percent
90%
Stage #1: Heating / reflux
Stage #2: at 30℃; for 1 h;
Example- 1 Preparation of amorphous Rabeprazole sodium3.03 gm of freshly cut clean sodium metal was dissolved in 500 ml of tert. butyl alcohol under nitrogen atmosphere by refluxing to give a clear solution which was cooled to about 25-300C. Rabeprazole (50 gm) was added to it at about 300C and stirred for about one hour to give an orange brown solution. The <n="7"/>reaction mass was treated with about 2.5 gm of activated charcoal and stirred at 27-300C for about one hour. The reaction mass was filtered using hyio bed and λvashed with about 50 ml of tert. butyl alcohol. The filtered solution was distilled under vacuum at 40-500C to remove lert.butyl alcohol, high vacuum was applied for about 30 min to remove traces of lert. butyl alcohol. 750 ml of diisopropyl ether were added to the viscous mass, and stirred under nitrogen at 27-300C for about one hour. Off-white, amorphous powder of rabeprazole-Na salt was obtained, which was filtered under nitrogen and washed with 50 ml of diisopropyl ether. The product was dried under vacuum at 65-700C for about 48 hours to give amorphous rabeprazole sodium. Wt. of rabeprazole sodium = 47 gms percent yield = 90 percent purity > 99 percent percent water by ICF. < 4 percent
83% With sodium hydroxide In water Example 1:Isolation of Rabeprazole sodium using ethyl acetate as solvent:Rabeprazole (50 gm) was dissolved in solution of sodium hydroxide (5.39 gm ) in demineralized water (162.5 ml). The solution was extracted with dichloromethane (100 ml) twice. The aqueous layer was then treated with neutral activated charcoal (1 gm) for 30 minutes at 28 to 35°C. Carbon was removed by filtration and the residue washed with demineralized water (12.5 ml). Ethyl alcohol (50 ml) was added to the clear filtrate. The solution was concentrated to thick mass under vacuum at 40 - 45°C. The thick mass was dissolved in ethyl alcohol (100 ml) and was again concentrated to a thick mass under vacuum at 40 - 45°C. The residue was then dissolved in ethyl acetate (100 ml) and the solution was concentrated to a thick oily mass under vacuum. The residue thus obtained was dissolved in ethyl acetate (100 ml) and the solution was added slowly over a period of 20 to 30 minutes to diisopropyl ether (500 ml). The slurry thus obtained was stirred for 60 minutes at 28 to 35°.. The solid was filtered and washed with diisopropyl ether. Then the solid was dried at 45 - 50° to get Rabeprazole sodium as a white amorphous solid (powder X-ray diffraction of the product does not show any sharp peak, shows only the base line), with mean particle diameter ranging between 10 to 50μm. Yield: 45 gm (85 percent), Assay: 99.5 percent (by HPLC). IR Spectra (KBr, cm'1): 3382, 2927, 1583, 1462, 1384, 1298, 1269, 1190, 1157, 1093, 1018, 745. H NMR Spectra [200 M Hz, CD3OD] δ (ppm): 8.23 - 8.25 (IH, d, ArH); 7.57 - 7.62 (2H, m, ArH); 7.0 - 7.09 (2H, m, ArH); 6.87 - 6.90 (IH, d, ArH); 4.57 - 4.63 (2H, d, O=S-CH2-Ar); 4.0 - 4.1 (2H, t, -O-CH2-CH2-); 3.49 - 3.55 (2H, t, -CH2-O-CH3); 3.31 (3H, s, -OCH3); 2.1 (3H, s, Ar-CH3); 1.96 - 2.0 (2H, t, -CH2-CH2-CH2-).; Example 2:Isolation of Rabeprazole sodium using dichloromethane as solvent:Rabeprazole (50 gm) was dissolved in solution of sodium hydroxide (5.4 gm) in demineralized water (150 ml). The solution was extracted with dichloromethane (100 ml) twice. The aqueous layer was then treated with neutral activated charcoal (1 gm) for 30 minutes at 28 to 35°C. Carbon was removed by filtration and the residue washed with EPO <DP n="7"/>demineralized water (12.5 ml). Ethyl alcohol (50 ml) was added to the clear filtrate. The solution was concentrated to thick mass under vacuum at 40 - 450C. The thick mass was dissolved in ethyl alcohol (100 ml) and was again concentrated to a thick mass under vacuum at 40 - 45°C. The residue was then dissolved in dichloromethane (150 ml) and the solution was filtered through 0.5-micron filter pad. The clear solution thus obtained was added slowly over a period of 20 to 30 minutes to diisopropyl ether (500 ml). The slurry thus obtained was stirred for 30 minutes at 28 to 35°. The solid was filtered and washed with diisopropyl ether. Then the solid was dried at 45 - 50° to get Rabeprazole sodium as a white amorphous solid (as evident from powder X-ray diffraction of the product), with mean particle diameter ranging between 15 to 55μm. Yield: 44 gm (83 percent), Assay: 99.5 percent (by HPLC)
72% With sodium hydroxide In hexane; dichloromethane at 10 - 20℃; for 4 h; A solution of 10 - ((0.029mol) 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]-methyl]thio]-1H-benzimidazole (condensate) Add 100ml toluene, 0.2 g of purified water, 8. lg (+) - L-diethyl tartrate, 4.5 g of titanium tetraisopropoxide, 52-55 ° C for lh; cooled to 25 ° C, 3.4 g of N, N-diisopropylethylamine, 4.5 g hydrogen peroxide cumene, 25-30 ° C reaction 2 h. After the oxidation reaction, with 2.5percent sodium hydroxide solution extraction 2 times, each 60ml, combined with sodium hydroxide solution, Add lg algae and lg activated carbon decolorization, the filtrate with saturated ammonium chloride solution to ρΗ = 9.7, the control temperature of 10-20 ° C, precipitation of white solid, crystallization lh after filtration. A 16 g dextroride dexeprazole was obtained (dry 8 g (0.022 mol 1)). 120 ml of dichloromethane and 300 ml of n-hexane were mixed and 0.88 g (0.022 mol) of sodium hydroxide solid was added with stirring. The control temperature is 10-20 ° C, Add dextrorolidazole wet to the above mixture, add finished, continue to control temperature 10-20 ° C 4h. The reaction was completed, filtered, washed, vacuum dried at 60 ° C, and dexamethasone was dissolved in sodium 7.2 g, yield: 72percent Purity: 99.81percent, sulfone:0.01percent.
64.94% With sodium hydroxide In methanolCooling with ice 39.76 g of rabeprazole was dissolved in 80 ml of methanol and added dropwise with sodium hydroxide in 80 ml of methanol under ice-cooling. After the addition was completed, the mixture was stirred at room temperature for 2 hours.Dried methanol, weighed 41.59 grams.Recrystallization from methyl tert-butyl ether and n-butanol, crystallization at room temperature, ice bath, filtration.Sampling measured content, sulfoxide content of 99.89percent, sulfone content of 0.07percent.The mixture was dried in vacuo and weighed 27.42 g in 64.94percent yield.Rabeprazole sodium salt NMR spectrum shown in Figure 1, thermogravimetric analysis showed that the product contains 1.0 crystal water (Figure 2).

Reference: [1] Patent: US2007/225502, 2007, A1, . Location in patent: Page/Page column 5
[2] Patent: US2007/225502, 2007, A1, . Location in patent: Page/Page column 8-9
[3] Patent: CN104119315, 2016, B, . Location in patent: Paragraph 0021; 0022
[4] Patent: WO2003/101452, 2003, A1, . Location in patent: Page 2
[5] Organic Process Research and Development, 2009, vol. 13, # 5, p. 896 - 899
[6] Patent: EP1452533, 2004, A1, . Location in patent: Page 8
[7] Patent: EP1452533, 2004, A1, . Location in patent: Page 9
[8] Patent: EP1452533, 2004, A1, . Location in patent: Page 8-9
[9] Patent: US2004/180935, 2004, A1, . Location in patent: Page/Page column 7
[10] Patent: WO2003/82858, 2003, A1, . Location in patent: Page/Page column 12-13
[11] Patent: WO2009/116072, 2009, A2, . Location in patent: Page/Page column 15-16
[12] Patent: CN106674198, 2017, A, . Location in patent: Paragraph 0026-0027
[13] Patent: EP1452533, 2004, A1, . Location in patent: Page 9
[14] Patent: US2004/180935, 2004, A1, . Location in patent: Page/Page column 6-7
[15] Patent: WO2003/82858, 2003, A1, . Location in patent: Page/Page column 13
[16] Patent: US2007/225502, 2007, A1, . Location in patent: Page/Page column 4-5
[17] Patent: WO2008/35192, 2008, A2, . Location in patent: Page/Page column 5
[18] Patent: WO2008/35192, 2008, A2, . Location in patent: Page/Page column 5
[19] Patent: WO2006/120701, 2006, A1, . Location in patent: Page/Page column 5; 6
[20] Patent: CN104311540, 2016, B, . Location in patent: Paragraph 0039-0040
[21] Patent: CN106317019, 2017, A, . Location in patent: Paragraph 0077; 0078; 0079; 0080
[22] Patent: EP1818331, 2007, A1, . Location in patent: Page/Page column 6
[23] Patent: WO2008/17020, 2008, A2, . Location in patent: Page/Page column 23-24
[24] Synthetic Communications, 2009, vol. 39, # 2, p. 278 - 290
[25] Patent: WO2009/133572, 2009, A2, . Location in patent: Page/Page column 7
[26] Patent: WO2010/6904, 2010, A2, . Location in patent: Page/Page column 19
[27] Patent: WO2010/4571, 2010, A2, . Location in patent: Page/Page column 3-4
[28] Patent: EP1921075, 2008, A2, . Location in patent: Page/Page column 8
[29] Patent: WO2011/4281, 2011, A1, . Location in patent: Page/Page column 4; 5
[30] Patent: WO2012/146643, 2012, A1, . Location in patent: Page/Page column 14; 15
[31] Patent: WO2014/91450, 2014, A1, . Location in patent: Page/Page column 16-17
[32] Patent: WO2008/155780, 2008, A2, . Location in patent: Page/Page column 11
[33] Patent: WO2008/155780, 2008, A2, . Location in patent: Page/Page column 12
  • 3
  • [ 117977-21-6 ]
  • [ 117976-90-6 ]
Reference: [1] Patent: WO2004/63188, 2004, A1, . Location in patent: Page 13
[2] Patent: WO2006/117802, 2006, A2, . Location in patent: Page/Page column 9-10
[3] Patent: WO2013/108068, 2013, A1, . Location in patent: Page/Page column 20; 21
[4] Patent: WO2014/91450, 2014, A1,
[5] Patent: CN103232437, 2016, B, . Location in patent: Paragraph 0033-0036
  • 4
  • [ 134469-07-1 ]
  • [ 117976-90-6 ]
Reference: [1] Patent: WO2006/117802, 2006, A2, . Location in patent: Page/Page column 8-9
  • 5
  • [ 117976-89-3 ]
  • [ 117976-47-3 ]
  • [ 117976-90-6 ]
YieldReaction ConditionsOperation in experiment
95% With sodium hydroxide In methanol at 0 - 50℃; for 4 - 5 h; Dissolve sodium hydroxide in methanol, stir to celerity. Add rabeprazole obtained in example 3 to it and stir at 45° - 5O0C for 4 to 5 h. Cool the reaction mixture to ca 250C, charge activated charcoal, stir and filter through celite bed. Collect the filtrate, distill under vacuum to remove methanol to obtain residue containing traces of methanol. Dissolve the residue in dichloromethane, add the solution with stirring to an alkane or ether solvent in an inert atmosphere to obtain amorphous powder of rabeproazole sodium which is dried under vacuum between 40°-45°C Yield: 95percent Purity: 99.5percent Sulphone impurity: 0.2percent (highest single impurity) Example 5: Sodium hydroxide is dissolved in methanol at 250C to 350C for an hour. To this solution, rabeprazole obtained in example 3 is added at a temperature between 0° to 50C and stirred for 3 to 4 hours to dissolve it completely. Then activated charcoal is added, stirred and filtered through c elite b ed. The filtrate thus obtained is distilled under vacuum at 40°-45°C to remove methanol to obtain a thick residue. To this residue, alkane or ether solvent is added with stirring to obtain amorphous powder of rabeprazole sodium, which is dried under vacuum between 40° to 450C. Yield: 95percent Purity: 99.5percent Sulphone impurity: 0.2percent (highest single impurity) Main advantages of the invention: 1) Provides process for obtaining rabeprazole in good yield and purity. 2) Provides process for preparing rabeprazole sodium exclusively in non-aqueous medium. 3) Provides simple and economical process for preparing rabeprazole sodium.
Reference: [1] Patent: WO2006/24890, 2006, A1, . Location in patent: Page/Page column 7
  • 6
  • [ 1310-73-2 ]
  • [ 117977-21-6 ]
  • [ 117976-90-6 ]
Reference: [1] Patent: WO2008/45777, 2008, A2, . Location in patent: Page/Page column 32
  • 7
  • [ 1310-73-2 ]
  • [ 117976-89-3 ]
  • [ 117976-90-6 ]
Reference: [1] Patent: WO2008/146297, 2008, A2, . Location in patent: Page/Page column 6
  • 8
  • [ 117977-20-5 ]
  • [ 117976-90-6 ]
Reference: [1] Patent: WO2014/91450, 2014, A1,
  • 9
  • [ 675198-19-3 ]
  • [ 117976-90-6 ]
Reference: [1] Patent: WO2014/91450, 2014, A1,
  • 10
  • [ 118175-10-3 ]
  • [ 117976-90-6 ]
Reference: [1] Patent: CN106674198, 2017, A,
  • 11
  • [ 134469-07-1 ]
  • [ 117976-90-6 ]
Reference: [1] Patent: CN106674198, 2017, A,
Same Skeleton Products
Historical Records

Similar Product of
[ 117976-90-6 ]

Chemical Structure| 117976-90-6

A101729[ 117976-90-6 ]

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Reason: Free-salt